Print

Israeli Drug Development Companies Are Poised For 505(b)(2) Development Process, Camargo Pharmaceutical Services Expert Says  
12/17/2013 9:55:28 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CINCINNATI--(BUSINESS WIRE)--Many Israeli pharmaceutical executives recently learned that the 505(b)(2) development process is an important tool that can significantly reduce costs and shorten the timeline for approval of new drugs, adding substantially to ROI.

Help employers find you! Check out all the jobs and post your resume.

//-->